Please assess the completion status of the following clinical trial:

Trial Title: A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient's parent or legal representative has provided informed consent~2. Must be receiving medical care in an intensive care unit~3. Age less than 18 years.~4. Body weight between ≥10 and ≤ 20 kilograms~5. Intent to receive full supportive care through aggressive management~6. Clinical diagnosis of AKI requiring CRRT~7. At least one non-renal organ failure OR presence of proven/suspected sepsis~Exclusion Criteria:~1. Threshold blood pressure of 80/40 mmHg~2. Patients with a solid organ transplant or those with a bone marrow or stem cell transplant in the previous 100 days or who have not engrafted~3. Acute or chronic use of circulatory support device, other than extracorporeal membrane oxygenation (ECMO)~4. Presence of preexisting advanced chronic renal failure on chronic renal replacement therapy or with an estimated glomerular filtration rate less than 30 mL/min/1.73m2~5. AKI occurring in the setting of burns, obstructive uropathy, scleroderma renal crisis, atheroembolism, functional or surgical nephrectomy, cyclosporine or tacrolimus nephrotoxicity~6. Metastatic malignancy which is actively being treated or may be treated by chemotherapy or radiation during the subsequent three month period after study therapy~7. Chronic immunosuppression with the exception of corticosteroids up to a dose of 10 mg of prednisone per day~8. Known positive HIV or AIDS or COVID-19~9. Current Do not Attempt Resuscitation (DNAR), Allow Natural Death (AND), or withdrawal of care status, or anticipated change in status within the next 7 days~10. Patient not expected to survive 28 days because of an irreversible medical condition~11. Any medical condition that the Investigator thinks may interfere with the study objectives~12. Treating clinician does not feel it is in the best interest of the patient~13. Platelet count \<15,000/mm3~14. Concurrent enrollment in another interventional clinical trial~15. Use of any other investigational drug or device within the previous 30 days~16. Use of AN-69 hemofilter membrane for CRRT

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- SCD Treatment (Type: OTHER): Pediatric patients receiving SCD + CRRT for up to 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).